Literature DB >> 8077718

Persistent acylation of high-molecular-weight penicillin-binding proteins by penicillin induces the postantibiotic effect in Streptococcus pyogenes.

S Yan1, G A Bohach, D L Stevens.   

Abstract

Penicillin at 10X MIC induced a postantibiotic effect (PAE) of 2.1 h in Streptococcus pyogenes. Progressive increases in the densities of penicillin-binding proteins (PBPs) 1-3 of the bacterium were detected at 30, 60, and 90 min during the postantibiotic phase. The increase in colony-forming units during this phase paralleled the kinetics of incorporation of lysine into proteins, suggesting that growth was triggered by de novo synthesis of PBPs. The question was raised as to whether the progressive increases in densities of PBPs were due to the restoration of preexisting PBPs or to synthesis of new PBPs. With 10X MIC of clindamycin to inhibit PBP synthesis during the postantibiotic phase, the temporal increase in densities of PBPs 1-3 were totally inhibited. These results suggest that the PAE of penicillin in S. pyogenes is caused by irreversible binding of penicillin to PBPs 1-3 and represents the time necessary for synthesis of new PBPs required for normal growth.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8077718     DOI: 10.1093/infdis/170.3.609

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  18 in total

1.  Postantibiotic leukocyte enhancement of meropenem against gram-positive and gram-negative strains.

Authors:  A Novelli; S Fallani; M I Cassetta; S Conti; T Mazzei
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

2.  Deletion of the multiple-drug efflux pump AcrAB in Escherichia coli prolongs the postantibiotic effect.

Authors:  William Stubbings; Julieanne Bostock; Eileen Ingham; Ian Chopra
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

3.  Pharmacodynamic model to describe the concentration-dependent selection of cefotaxime-resistant Escherichia coli.

Authors:  Sara K Olofsson; Patricia Geli; Dan I Andersson; Otto Cars
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

4.  Modeling the mechanism of postantibiotic effect and determining implications for dosing regimens.

Authors:  Patricia Geli
Journal:  J Math Biol       Date:  2009-02-03       Impact factor: 2.259

5.  Pharmacodynamic effects of sub-MICs of benzylpenicillin against Streptococcus pyogenes in a newly developed in vitro kinetic model.

Authors:  E Löwdin; I Odenholt; S Bengtsson; O Cars
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

6.  In vitro antimicrobial effects of various combinations of penicillin and clindamycin against four strains of Streptococcus pyogenes.

Authors:  D L Stevens; K J Madaras-Kelly; D M Richards
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

7.  Characteristics and dynamics of bacterial populations during postantibiotic effect determined by flow cytometry.

Authors:  M Gottfredsson; H Erlendsdóttir; A Sigfússon; S Gudmundsson
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

8.  Correlating Drug-Target Residence Time and Post-antibiotic Effect: Insight into Target Vulnerability.

Authors:  Shabnam Davoodi; Fereidoon Daryaee; Andrew Chang; Stephen G Walker; Peter J Tonge
Journal:  ACS Infect Dis       Date:  2020-02-14       Impact factor: 5.084

9.  Studies of the killing kinetics of benzylpenicillin, cefuroxime, azithromycin, and sparfloxacin on bacteria in the postantibiotic phase.

Authors:  I Odenholt; E Löwdin; O Cars
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

10.  Effects of selective and nonselective nonsteroidal anti-inflammatory drugs on antibiotic efficacy of experimental group A streptococcal myonecrosis.

Authors:  Stephanie M Hamilton; Clifford R Bayer; Dennis L Stevens; Amy E Bryant
Journal:  J Infect Dis       Date:  2013-11-11       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.